TRT and Fertility: What Men Need to Know Before Starting

Testosterone replacement therapy improves energy, body composition, mood, libido, and cognitive function in men with documented deficiency. It also suppresses sperm production. This is not a side effect. It is a direct pharmacological consequence that every man of reproductive age must understand before starting treatment.

The mechanism is straightforward, and the clinical implications are significant.

How TRT Suppresses Fertility

The hypothalamic-pituitary-gonadal (HPG) axis operates on a feedback loop. The hypothalamus releases GnRH (gonadotropin releasing hormone), which signals the pituitary to release LH (luteinizing hormone) and FSH (follicle stimulating hormone). LH stimulates the Leydig cells in the testes to produce testosterone. FSH stimulates the Sertoli cells to support spermatogenesis.

When exogenous testosterone is administered, whether by injection, cream, or any other route, the hypothalamus and pituitary detect the elevated circulating testosterone and reduce their output of GnRH, LH, and FSH accordingly. The system interprets the external supply as evidence that production is sufficient and scales back.

The consequences for the testes are direct. Reduced LH means reduced intratesticular testosterone production. Reduced FSH means reduced support for sperm maturation. Spermatogenesis requires high local concentrations of testosterone within the testes, concentrations that systemic TRT does not produce. The result, in most men on TRT, is a significant reduction or complete cessation of sperm production.

Testicular volume typically decreases as well, reflecting the reduced activity of both Leydig and Sertoli cells.

How Quickly Does It Happen

Sperm production declines within weeks of starting TRT. Most men will show significantly reduced sperm counts within 2 to 3 months, and many will become azoospermic (zero sperm in the ejaculate) within 4 to 6 months. The timeline varies between individuals based on age, baseline fertility status, and the degree of HPG axis suppression, but the direction is consistent and predictable.

Data from controlled studies consistently demonstrate that approximately 65 percent of men on testosterone therapy become azoospermic, with the remainder showing severely reduced counts. This is not a rare side effect or an outlier finding. This is the expected pharmacological outcome in the majority of men who take exogenous testosterone.

Is It Reversible

In most cases, spermatogenesis recovers after discontinuation of TRT, but recovery is not guaranteed and the timeline is variable. The duration of therapy and individual HPG axis resilience play large roles.

Studies suggest that the majority of men recover sperm production within 6 to 12 months of stopping testosterone therapy. Some recover within 3 to 4 months. A minority take 12 to 24 months or longer. Published data indicates that approximately 5 to 10 percent of men may not fully recover their baseline sperm parameters, particularly men who were on therapy for extended periods or who have other factors that compromise HPG axis function (age, metabolic dysfunction, prior fertility issues).

Recovery depends on multiple factors: the duration of TRT use, the patient’s age, baseline fertility status prior to treatment, the degree of suppression achieved during therapy, and individual variation in HPG axis resilience. A 35-year-old man on TRT for one year is far more likely to have rapid, complete recovery than a 50-year-old man on therapy for five years. This is not a guarantee. It is a probability.

The Critical Conversation

Every man of reproductive age considering TRT must be asked a direct question: do you want the option of having biological children in the future? If the answer is yes, or even “maybe,” the treatment plan must account for this from the beginning.

This conversation does not happen often enough in clinical practice. Many men are prescribed testosterone without being informed about its contraceptive effect. Some learn about it only when they and their partner fail to conceive months or years into therapy, at which point recovery becomes a clinical urgency rather than a planned strategy. By that time, the decision to pursue alternatives like hCG or to discontinue therapy carries a much higher emotional and relational cost. Informed consent requires anticipating this question before therapy begins.

Alternatives That Preserve Fertility

For men who want the benefits of improved testosterone levels without sacrificing fertility, several alternatives exist.

Clomiphene Citrate (Clomid)

Clomiphene is a selective estrogen receptor modulator (SERM) that blocks estrogen’s negative feedback on the hypothalamus and pituitary. The result is increased GnRH, LH, and FSH secretion, which stimulates the testes to produce more testosterone endogenously while maintaining, and sometimes improving, spermatogenesis.

Clomiphene is used off-label for this purpose and is well studied in the male hypogonadism literature. It does not produce the same magnitude of testosterone increase as exogenous TRT but can meaningfully improve levels while keeping the HPG axis active.

Human Chorionic Gonadotropin (hCG)

hCG mimics LH and directly stimulates the Leydig cells to produce testosterone. Because it preserves intratesticular testosterone concentrations, it supports both testosterone levels and spermatogenesis.

hCG can be used as a standalone therapy or in combination with low-dose exogenous testosterone. When combined with TRT, hCG partially mitigates the suppressive effect on spermatogenesis by maintaining the LH-like signal that TRT eliminates.

The dosing and monitoring of hCG require physician oversight and regular blood work to ensure appropriate hormone levels and to avoid overstimulation.

Semen Cryopreservation

For men who decide to proceed with TRT and want to protect their future reproductive options, semen banking before starting treatment is a straightforward precaution. Samples are collected, analyzed, and stored at a cryopreservation facility.

This approach provides insurance regardless of what happens to spermatogenesis during treatment. It is particularly advisable for men starting TRT in their 30s who are uncertain about future family plans.

Planning the Protocol

A responsible approach to testosterone therapy in men of reproductive age involves several steps.

First, assess fertility status before treatment. A semen analysis provides baseline data on sperm count, motility, and morphology. This establishes what the patient is starting with and serves as the reference point for any future recovery assessment.

Second, discuss timing and priorities. If the patient is actively trying to conceive, TRT should be deferred. If conception is planned within the next 1 to 2 years, alternatives like clomiphene or hCG are more appropriate. If fatherhood is a remote or uncertain possibility, semen cryopreservation combined with TRT may be the best balance.

Third, monitor during treatment. If hCG is used alongside TRT, regular semen analyses confirm that spermatogenesis is being maintained. LH and FSH levels indicate the degree of HPG axis suppression.

Fourth, plan for discontinuation if needed. If a man on TRT decides he wants to conceive, a structured protocol to taper TRT and introduce hCG or clomiphene to restart the HPG axis can facilitate recovery. This process requires patience, medical supervision, and realistic expectations about the timeline.

What to Ask Your Physician

Before starting TRT, every man should ask: How will this affect my fertility? What options do I have to preserve sperm production? What is the plan if I want to conceive while on therapy or after stopping?

A physician who cannot answer these questions in detail is not the right physician to manage your testosterone therapy.

Continue Reading

If you found this useful, these related articles may deepen your understanding:

• Testosterone Delivery Methods
• The Blood Work You Need Before Starting Testosterone
• Testosterone and Cardiovascular Health: What the Research Actually Shows

---

Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario pharmacy partner. To learn more or book a virtual consultation, visit manussolis.ca.